Cleveland Clinic researchers have demonstrated in animal studies that vaccination against alpha-lactalbumin completely prevented breast cancer in mice that were specifically bred to develop breast cancer. Studies have been published and are available: Cancers 2016, 8, 56; doi10.3390/cancers8060056. (https://www.mdpi.com/2072-6694/8/6/56).
For more information on the ongoing clinical trial of our breast cancer vaccine, please go to the trial’s page on clinicaltrials.gov:
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer - Full Text View - ClinicalTrials.gov.
Cleveland Clinic researchers have demonstrated in animal models that vaccination against the extracellular domain of anti-Mullerian hormone receptor II (AMHR2-ED) significantly inhibits tumor growth and enhances overall survival. The results indicate that vaccinating women against AMHR2-ED could provide safe and effective preemptive immunity against epithelial ovarian carcinoma, the most common form of ovarian cancer. Studies have been published and are available: Cancer Prev Res; 10(11); 612-624 (https://doi.org/10.1158/1940-6207.CAPR-17-0154).
Sign up for email Updates
Be The First to Receive Breaking NewsSign Up Now